Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 5/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980764 | 0.87 | MRGPRX4 (0.54) | LMNAL3MBTL1EGFRERBB2KDM4E | |
| SCHEMBL9975357 | 0.86 | EGFR (0.65) | EGFRERBB2GAK | |
| SCHEMBL21340751 | 0.86 | EGFR (0.53) | LMNAL3MBTL1EGFRERBB2KDM4E | |
| SCHEMBL22967382 | 0.86 | LMNA (0.52) | LMNAL3MBTL1EGFRERBB2KDM4E | |
| SCHEMBL6961120 | 0.85 | LMNA (0.47) | LMNAL3MBTL1EGFRERBB2KDM4E | |
| SCHEMBL14548610 | 0.84 | LMNA (0.52) | LMNAL3MBTL1EGFRERBB2KDM4E | |
| SCHEMBL6980756 | 0.83 | LMNA (0.45) | LMNAL3MBTL1EGFRERBB2KDM4E | |
| SCHEMBL4343925 | 0.81 | MAOB (0.65) | LMNAKDM4EALDH1A1PLA2G1BGAA | |
| SCHEMBL3649956 | 0.79 | FFAR1 (0.48) | L3MBTL1EGFRERBB2MAOBMRGPRX4 | |
| SCHEMBL3321494 | 0.78 | MAOB (0.65) | LMNAL3MBTL1MAPTMAOBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760633-B1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2021-12-15 | — | — | EP | disclosed |
| EP-3760633-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2019170088-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | 北京赛特明强医药科技有限公司 | 2019-09-12 | — | — | WO | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | LMNA 4634/4885L3MBTL1 4646/4885EGFR 2/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | LMNA 4634/4885L3MBTL1 4646/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.